ORIGINAL RESEARCH article
Front. Neurol.
Sec. Neuro-Otology
Volume 16 - 2025 | doi: 10.3389/fneur.2025.1660767
Assessment of Raftlin and Blood Count Parameters in Otosclerosis
Provisionally accepted- 1Kocaeli City Hospital, İzmit, Türkiye
- 2Faculty of Medicine, Zonguldak Bulent Ecevit University, Zonguldak, Türkiye
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Objective: Although otosclerosis is a common disease, its etiology has not yet been clearly elucidated. One of the factors recently implicated in its pathogenesis is chronic inflammation.Blood count parameters are known as classical inflammatory markers in several diseases.Raftlin is also a novel biomarker of inflammation. The present study aimed to investigate Raftlin levels and blood count parameters in otosclerosis.The study included 50 otosclerosis patients and 50 healthy volunteers. Serum Raftlin levels and white blood cell, neutrophil, lymphocyte and platelet counts, neutrophil to lymphocyte ratio (NLR), platelet to lymphocyte ratio (PLR), and mean platelet volume (MPV)were measured in otosclerosis patients and compared with the controls.Results: White blood cell and neutrophil counts and NLR were statistically higher in otosclerosis patients than in the control group (p<0.001). There was no statistically significant difference between the control and patient groups in lymphocyte and platelet counts, and MPV and PLR values. The Raftlin level was also statistically significantly higher in otosclerosis patients than in the control group (p=0.001).The Raftlin level and NLR value were significantly higher in otosclerotic patients than in healthy controls, supporting the presence of an inflammatory etiology for otosclerosis.Our study is the first in the literature to investigate the relationship between otosclerosis and Raftlin with known inflammatory markers.
Keywords: Otosclerosis, Blood Cell Count, Inflammation Mediators, Raftlin, Hearing - disorders
Received: 07 Jul 2025; Accepted: 13 Aug 2025.
Copyright: © 2025 eliçora, erdem, güven and Baklaci. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Deniz Baklaci, Faculty of Medicine, Zonguldak Bulent Ecevit University, Zonguldak, Türkiye
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.